BB 10010

Drug Profile

BB 10010

Alternative Names: Macrophage inflammatory protein-1-alpha analogue; MIP-1alpha variant; Nagrestip

Latest Information Update: 07 May 2003

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator British Biotech
  • Class Radioprotectives
  • Mechanism of Action Immunosuppressants; Mitosis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chemotherapy-induced damage; HIV infections; Myeloid leukaemia; Radiation injuries

Most Recent Events

  • 07 May 2003 A study has been added to the Cancer therapeutic trials section
  • 29 Feb 2000 Preclinical development for Chemotherapy induced damage (Prevention)/Chemoprotection in United Kingdom (Unknown route)
  • 29 Feb 2000 A preclinical study has been added to the pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top